Results 61 to 70 of about 7,444 (141)

Medications That Regulate Pregnane X Receptor: A Systematic Review of Current Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
PRISMA 2020 flow diagram of study selection for this systematic review of medications that regulate the pregnane X receptor (PXR), from 12 236 records screened to 101 included studies. ABSTRACT The pregnane X receptor (PXR) gene encodes a ligand‐activated protein involved with the metabolism and excretion of drugs, toxins, and other xenobiotics.
Petra Czarniak, Rachael Moorin, Jeff Hughes, Karl Gruber, David Youens   +4 more
wiley   +1 more source

Frequent high-level rifaximin resistance in Escherichia coli associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study

Microbiology Spectrum
We conducted a prospective, controlled study to assess the prevalence of high-level rifaximin resistance in intestinal Escherichia coli (E. coli) among patients with liver cirrhosis (LC).
L. Boll, W. V. Kern, S. Schuster, M. Schultheiß, C. Schneider, M. Vavra, R. Thimme, S. Rieg, J. Camp   +8 more
doaj   +1 more source

C-Reactive Protein Levels Predict Improvement in the Liver Functional Reserve by Long-Term Rifaximin Treatment

Diseases
Objectives: Rifaximin is a non-absorbable antibiotic that has an efficacy for hepatic encephalopathy (HE). We previously demonstrated that rifaximin improved liver functional reserve, but this was a single-center study with a limited number of cases, and
Kensuke Kitsugi, Kazuhito Kawata, Go Murohisa, Yashiro Yoshizawa, Masaharu Kimata, Yosuke Kobayashi, Shuhei Unno, Hidenao Noritake, Takeshi Chida, Yoshisuke Hosoda   +9 more
doaj   +1 more source

Rifaximin

Gastroenterologie a hepatologie, 2017
  +5 more sources

The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy

Therapeutic Advances in Gastroenterology, 2019
Background: After 5  years since the registration of rifaximin-α as a secondary prophylaxis for overt hepatic encephalopathy (HE) in the Netherlands, we aimed to evaluate the use of hospital resources and safety of rifaximin-α treatment in a real-world ...
Rosalie C. Oey, Lennart E.M. Buck, Nicole S. Erler, Henk R. van Buuren, Robert A. de Man   +4 more
doaj   +1 more source

Synthesis rifaximin with copper (Rif-Cu) and copper oxide (Rif-CuO) nanoparticles Considerable dye decolorization: An application of aerobic oxidation of eco-friendly sustainable approach

Heliyon
In this study, rifaximin with copper (Cu) and copper oxide (CuO) nanoparticles (NPs) were synthesised. The resultant CuO nanoparticles were used to degrade Rhodamine B (RhB) and Coomassie Brilliant Blue (G250).
Janani Mullaivendhan, Idhayadhulla Akbar, Anis Ahamed, Hissah Abdulrahman Alodaini   +3 more
doaj   +1 more source

Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial

Therapeutic Advances in Gastroenterology, 2017
Background: Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D.
Brooks D. Cash, Mark Pimentel, Satish S. C. Rao, Leonard Weinstock, Lin Chang, Zeev Heimanson, Anthony Lembo   +6 more
doaj   +1 more source

Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4/NFκB pathway

Scientific Reports
Metabolic dysfunction-associated steatohepatitis (MASH) has become a serious public health problem, posing an increasingly dangerous threat to human health owing to its increasing prevalence and accompanying intra- and extrahepatic adverse outcomes ...
Ting Qiu, Xiaodong Zhu, Jingju Wu, Wenyuan Hong, Weitao Hu, Taiyong Fang   +5 more
doaj   +1 more source

Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis

BMC Gastroenterology
Background Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that affects the prognosis of patients with liver disease and is considered an independent risk factor for hospitalization and death. Rifaximin has been approved for HE treatment. This
Guihua Fang, Shuna Liu, Bin Liu
doaj   +1 more source

Correction to “The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis”

Portal Hypertension &Cirrhosis, Volume 5, Issue 3, Page 304-305, September 2026.
wiley   +1 more source